Neuropilin-1 Expression Identifies a Subset of Regulatory T Cells in Human Lymph Nodes That is Modulated by Preoperative Chemoradiation Therapy in Cervical Cancer
Overview
Authors
Affiliations
We examined the phenotype and function of CD4+ T cells expressing the semaphorin III receptor neuropilin-1 (Nrp1) in human lymph nodes and peripheral blood. In lymph nodes, Nrp1 identified a small regulatory CD4+ CD25(high) T-cell subpopulation (Nrp1+ Treg) that expressed higher levels of Forkhead box P3 (Foxp3) message and protein than Nrp1- Treg, and various molecular markers of activated Treg, i.e. CD45RO, human leucocyte antigen (HLA)-DR and glucocorticoid-induced tumour necrosis factor receptor (GITR). Similarly to conventional Treg, Nrp1+ Treg proliferated poorly in vitro, and exerted contact-dependent in vitro suppression of T-cell proliferation and cytokine secretion. However, Nrp1+ Treg were more efficient than Nrp1- Treg at inducing suppression. Nrp1 was also expressed on a small subpopulation of CD25(int) and CD25- CD4+ T cells that expressed more Foxp3, CD45RO, HLA-DR and GITR than their Nrp1- counterparts. In contrast, in peripheral blood Nrp1 identified a minor CD4+ T-cell subset that did not display the phenotypic features of Treg lacking Foxp3 expression and marginally expressing CD25. Hence, the function of Nrp1+ CD4+ T cells seemingly depends on their anatomical location. In a previous report, we proposed that Treg may curb the anti-tumour T-cell response in cervical cancer. We show here that Treg and Nrp1+ Treg levels dropped in the tumour-draining lymph nodes of patients with cervical cancer following preoperative chemoradiotherapy in a direct relationship with the reduction of tumour mass, suggesting that suppressor cell elimination facilitated the generation of T cells mediating the destruction of the neoplastic cells left behind after cytotoxic therapy.
Zhang B, Liu Q, Li L, Ye Y, Guo X, Xu W Cancer Immunol Immunother. 2025; 74(2):50.
PMID: 39751948 PMC: 11699024. DOI: 10.1007/s00262-024-03893-1.
Hohlstein P, Schumacher E, Abu Jhaisha S, Adams J, Pollmanns M, Schneider C Int J Mol Sci. 2024; 25(10).
PMID: 38791476 PMC: 11121523. DOI: 10.3390/ijms25105438.
Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity.
Santosh Nirmala S, Kayani K, Gliwinski M, Hu Y, Iwaszkiewicz-Grzes D, Piotrowska-Mieczkowska M Front Immunol. 2024; 14:1321228.
PMID: 38283365 PMC: 10811018. DOI: 10.3389/fimmu.2023.1321228.
Investigating the potential mechanism of quercetin against cervical cancer.
Chu M, Ji H, Li K, Liu H, Peng M, Wang Z Discov Oncol. 2023; 14(1):170.
PMID: 37704909 PMC: 10499770. DOI: 10.1007/s12672-023-00788-y.
Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives.
Kielb P, Kowalczyk K, Gurwin A, Nowak L, Krajewski W, Sosnowski R Biomedicines. 2023; 11(6).
PMID: 37371647 PMC: 10295349. DOI: 10.3390/biomedicines11061552.